Rasmussen encephalitis (RE) is a rare neurological disorder characterized by unilateral inflammation of cerebral cortex and other structures, most notably the hippocampus, progressive cognitive deterioration, and pharmacoresistant focal epilepsy. The pathogenesis of RE with unilateral cortical atrophy and focal seizures is still enigmatic. Activation of adenosine A1 receptors (A1R) has been proven to prevent the spatial spread of seizures. We hypothesized that the epileptogenic mechanisms underlying RE are related to changes in neuronal A1R expression. Immunnohistochemistry was used to examine the expression of A1R and adenosine kinase (ADK) in cortical specimens from RE (n ¼ 12), and compared with control cortical tissue. The quantification of A1R and ADK expression was evaluated by Western blot. A1R was predominantly localized in perinuclear of neurons and not in astrocytes or microglia. Upregulation of neuronal A1R was observed in the lesions of RE. Reactive astrocytes and subpopulation of remaining neurons demonstrated over-expression of the ADK within the lesions of RE. Significant increase of A1R and ADK expression in RE compared with controls was confirmed by Western blot. These results suggest that overexpression of ADK is a common pathologic hallmark of RE, and that upregulation of neuronal A1R in RE is crucial in preventing the spread of seizures.
INTRODUCTION
Rasmussen encephalitis (RE) is a very rare chronic progressive inflammatory neurological disorder of uncertain etiology affecting mostly children and associated with hemispheric atrophy, pharmacoresistant focal epilepsy (epilepsia partialis continua [EPC]), cognitive deterioration and progressive neurological deficits, resulting from progressive loss of function subserved by the involved cerebral hemisphere (1) (2) (3) (4) (5) . The primary cause of RE remains unknown and targeted therapeutic strategies remain elusive. The etiology and pathogenesis of RE, in particular, the factors responsible for the characteristic of asymmetry are still unclear. The neuropathological hallmarks of RE consist of lymphocytic infiltrates (perivascular lymphocytic cuffing), microglial nodules, neuronal destruction, and gliosis of the affected hemisphere (6, 7) . RE is an inflammatory disorder of the central nervous system, even if the underlying cause of the inflammation (ie infection, autoimmunity) has not been proven. Increasing evidence strongly supports the hypothesis of an antigen-driven MHC class-I restricted, CD8þ T cell-mediated attack against neurons and astrocytes in the CNS dominating the pathogenesis in RE in contrast to a random attraction of cells as part of a secondary immune response (8) . Our recent work demonstrated that activation of endogenous high-mobility group box-1 and Toll-like receptors indicates the novel targets in the treatment of epilepsy associated with RE (9, 10) , and increased reactive astrocyte expression of major adenosine-removing enzyme adenosine kinase (ADK) in RE patients plays an important role in the epileptogensis of RE (11, 12) .
Focal seizures and cognitive decline are prominent clinical features of RE and recent data suggest that the dysregulation of adenosinergic mechanism is involved in the development of epilepsy and its comorbidities (13) . Maladaptive changes in adenosine homeostasis can not only give rise to epileptic seizures, inflammation, but also give rise to comorbidities commonly associated with epilepsy (12) (13) (14) . Adenosine is an endogenous purine nucleoside that modulates a wide range of physiologic functions (15) . Most notable among its many roles is its importance in controlling inflammation (16) , inhibiting seizures (17) (18) (19) (20) (21) , and restoring cognitive function when cognition is impaired secondary to epilepsy (13) . Endogenous adenosine acting at adenosine A1 receptors (A1R) is an important seizures-control mechanism (22, 23) . ADK, the main adenosine-removing enzyme, has been highlighted as a diagnostic marker to predict epileptogenesis as well as a potential target for antiepileptogenesis or disease modification (13, 18, 24, 25) . Deletion of A1Rs or increased adenosine clearance by overexpression of ADK (which should reduce A1R activation) both causes spontaneous electrographic seizures (18, 19, 25) and leads to lethal status epilepticus following the intrahippocampal injection of kainic acid in rodent models of epilepsy (26) .
Increasing clinical evidence from specimen surgically resected from patients with pharmacoresistant epilepsy also demonstrated that adenosine dysfunction contributing to seizures generation in human chronic epilepsy. Adenosine deficiency in microdialysis samples from epileptogenic hippocampus was demonstrated in human patients with TLE (27) . Overexpression of astroglial ADK was found within the epileptic foci in temporal lobe epilepsy (19, 28) , Rasmussen encephalitis (11), astroglial tumor-related epilepsy (29) , and focal cortical dysplasia (30) . Genetic variation in ADK was indicated associating with posttraumatic epilepsy development and contributing to explaining variability in time to first seizure and posttraumatic epilepsy risk (31) ; loss of A1R in human temporal lobe epilepsy may contribute to the human epileptic condition (32) . Selective activation of A1R mediated a strong anticonvulsant action in human neocortical slices from patients with temporal lobe epilepsy (with 73% of human temporal cortex slices completely suppressed seizure-like events) (23) . On the other hand, variants in the A1R gene associated with the development of posttraumatic seizures after a severe traumatic brain injury and indicated that deficiency in A1R signaling might be associated with posttraumatic epileptogenesis (33) .
Given the evidence that adenosine signaling plays a crucial role in preventing seizures and inflammation, and that activation of A1R has been proved to prevent the spread of seizures, we hypothesized that the epileptogenic mechanisms underlying RE might be related to changes in A1R expression.
MATERIALS AND METHODS

Patients and Diagnosis
The local Ethics Committee (Beijing Sanbo Hospital, Capital Medical University, China) approved all studies and clinical investigations were conducted according to the declaration of Helsinki. Informed consent was obtained from all participants or their parents or legal guardians.
In this study, brain tissue were from banked on cases previously diagnosed as having RE including from their resection specimens neuropathological analyses. All of the 12 childhood-onset RE patients were diagnosed with RE according to the typical clinical, MRI and neuropathological findings as proposed in (3) . Presurgical evaluation in Beijing Sanbo Hospital included MRI (spin-echo T1-weighted axial and T2-weighted axial, coronal sequences and fluid-attenuated inversion recovery images with 5-mm-thick axial, sagittal, coronal sections), fluorodeoxyglucose positron emission tomography (FDG-PET), scalp video electroencephalography (EEG), intracranial EEG monitoring, seizures semiology analysis as well as neuropsychological test. Interictal/ictal scalp EEG was recorded using a video EEG monitoring system (Nicolet vEEG; Viasys Healthcare, Madison, WI), with electrodes placed according to the international 10-20 system for all patients. The duration of video EEG monitoring ranged from 1-3 days, and at least 3 habitual seizures were recorded. The main ictal manifestations were categorized according to the semiological seizures classification (34) .
Twelve patients with RE were identified in the neuropathology archives at Sanbo Brain Hospital, diagnosed between January 2004 and August 2011. There were 6 male and 6 female patients, with a mean age of seizures onset of 5. 25 3-6.75 ). According to the Engel's criteria, all patients were Engel Class I. Epilepsy was the first manifestation of the condition in all patients. None of the patients had a relevant perinatal history before the onset of the disease. Clinical details of the patient cohort are summarized in Table 1 . Brain samples from all 12 RE patients were obtained during neurosurgical operations (functional hemispherectomies or anatomical hemispherectomies). Brain tissue (frontal cortex) obtained from all patients was paraffinembedded. In 5 of these 12 patients, parts of the brain samples were cryoprotected in addition for Western blot analysis. For comparison, 6 neocortical specimens (5 frontal cortex, 1 occipital cortex) were obtained from a significant amount of well outside the lesion tissue (normal-appearing cortex/white matter adjacent to the lesion) resection for intractable epilepsy in patients with focal cortical dysplasia in the study. Of note, microscopic evaluation was performed on those areas to discard microscopic changes related to dysplasia (Fig. 1) , in order to avoid perilesion tissue within the border zone between the lesion and normal-appearing cortex, as the extent of neuropathological abnormalities in this area may vary among subjects. See Table 1 for further demographic data.
Tissue Preparation
Formalin-fixed, paraffin-embedded tissue samples were sectioned at 4 lm and mounted on precoated glass slides (Star Frost, Waldemar Knittel GmbH, Braunschweig, Germany). Sections of all specimens were processed for hematoxylin and eosin (H&E), CD8, CD3 as well as for immunohistochemical stainings for a neuronal marker NeuN, glial marker glial fibrillary acidic protein (GFAP), A1R, and ADK, which are described below. Brain tissue from RE patients (n ¼ 5) and surgical controls (n ¼ 5) was snap frozen in liquid nitrogen and stored at À80 C until further use (Western blot analysis). 
Immunohistochemistry
Antibodies to A1R (monoclonal rabbit ab124780, 1:100, Abcam, Cambridge, UK), Iba-1 (monoclonal mouse ab15690, 1:300, Abcam), GFAP (monoclonal mouse, DAKO; Glostrup, Denmark, 1:4000), neuronal nuclear protein (NeuN; mouse clone MAB377, IgG1; Chemicon, Temecula, CA; 1:2000), CD8 (mouse-IgG, clone C8/144B, from Dako Cytomation, 1:50), CD3 (rabbit-IgG, clone SP7, from Lab Vision, Fremont, CA, 1:500), and ADK (Provided by professor Detlev Boison, R.S. Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR. polyclonal rabbit, 1:500) (18, 19, 30) were used in the routine immunohistochemical analysis of RE human specimens. Double-label immunocytochemistry was performed as described previously (18, 30) . Sections after incubation with primary antibodies, were incubated for 2 h at room temperature with Alexa Fluor 568 and Alexa Fluor 488 (antirabbit IgG or antimouse IgG; 1:200; Molecular Probes, Eugene, OR). Images were visualized using a Leica microscope under Ex/Em wavelength of 500/550 nm (green), collected using an Optronics DEI-750 three-chip camera equipped with a BQ 8000 sVGA frame grabber, and analyzed using Bioquant software (Nashville, TN).
A semiquantitative immunohistochemistry gradient analysis of the test tissue from most to least inflamed/neurondepleted area was constructed for analysis of differences in ADK and A1R immunostaining. For the immunohistochemical detection of ADK and A1R immunostaining, we followed our previously published procedures with modification (18, 25, 35) . A morphometric neuronal count of A1R stained neurons was performed in a defined area of the lesion (434 lm Â 326 lm) in the mild, moderate and severely inflamed areas, Levels of A1R in each analysis field were initially measured as arbitrary density units/A1R-stained neurons, and subsequently expressed as a percent change from control A1R. Corresponding fields from each RE patient (n ¼ 12) and surgical controls (n ¼ 6) were analyzed by scanning ADK and A1R immunofluorescence on DAB stained slices using a Kodak imaging device.
Western Blot Analysis
Preparation and analysis of Western blots were performed as described previously (11, 30) with modification. Freshly frozen histologically normal surgical control cerebral cortex (n ¼ 5) and RE samples (n ¼ 5, patients 7-11 in Table 1 ) were homogenized in lysis buffer containing 10 mM Tris (pH 8.0), 150 mM NaCl, 10% glycerol, 1% NP-40, Na-orthevanadate (10.4 mg/mL), 5 mM EDTA (pH 8.0), 5 mM NaF, and protease inhibitor cocktail (Boehringer Mannheim, Germany). Protein content was determined using the bicinchoninic acid method. For electrophoresis, equal amounts of proteins (30 lg/lane) were separated by sodium dodecylsulfate-polyacrylamide gel electrophoretic (SDS-PAGE) analysis. Separated proteins were transferred to nitrocellulose paper for 1 hour and 30 minutes, using a semidry electroblotting system (BioRad, Transblot SD, Hercules, CA). Blots were incubated overnight in TTBS (20 mM Tris, 150 mM NaCl, 0.1% Tween, pH 7.5)/5% nonfat dry milk, containing the primary antibody A1R (monoclonal rabbit ab124780, 1:100, Abcam), ADK (polyclonal rabbit, 1:5000, After several washes in TTBS, the membranes were incubated in TTBS/5% nonfat dry milk/1% BSA, containing the goat antirabbit or goat antimouse antibodies coupled to horseradish peroxidase (1:2500; Dako) for 1 hour. After washes in TTBS, immunoreactivity was visualized using Lumi-light PLUS Western blotting substrate (Roche Diagnostics, Mannheim, Germany) and digitized using a Luminescent Image Analyzer (LAS-3000, Fuji Film, Japan). Expression of b-actin (monoclonal mouse, Sigma, St. Louis, MO, 1:50,000) was used as reference. ADK and A1R levels were normalized to internal standards and reported relative to control.
Statistical Analysis
Quantitative data were analyzed using GraphPAD Prism software (GraphPAD Software, La Jolla, CA). Data for ADK and A1R immunohistochemistry quantification analyzed using one-way ANOVA followed by Newman-Keuls test. Data for ADK and A1R Western blot quantification analyzed using two-tailed Student t-test. p < 0.05 was considered significant.
RESULTS
Clinical Features
The clinical features of the cases included in this study are summarized in Table 1 . All 12 patients had refractory epilepsy and underwent surgical resection for intractable seizures. 11 of 12 patients in the study cohort were in the acute stage of RE and 1 of 12 patients was in residual stage, according to Bien's stagewise course of RE (2, 3). The seizures types of patients in our study included simple partial seizures, EPC, complex partial seizures and secondary generalized tonic clonic seizures. EPC was defined as regular or irregular clonic muscular twitches affecting a limited part of the body, occurring for a minimum of 1 hour, and recurring at intervals of no >10 seconds (36) ( Table 1 ).
All patients underwent MRI at least 2 times from the first seizures until the age of surgery that were available for evaluation. MRI was abnormal in all patients. Serial MRIs (axial T2-weighted fluid-attenuated inversion recovery image) typically show progression of signal change and unihemispheric focal cortical atrophy before surgery treatment in all cases ( Fig. 2A-D) . Long-term video EEG results were abnormal in all cases, indicating unilateral epileptic discharge in all patients with or without unihemispheric slowing (Fig. 2E) . EPC is not always accompanied by visually recognizable ictal surface EEG activity (4) . The features of inflammatory pathology of RE patients characterized by perivascular cuffing (Fig. 3A, D) and parenchymal (Fig. 3E ) lymphocytic infiltrates CD8þ Tlymphocytes, double label of CD3 and CD8 revealing most of the infiltrating lymphocyte are CD8 þ CD3þ positive T-lymphocytes (Fig. 3E, inset) , neuronal loss (Fig. 3C ), reactive astrogliosis (Fig. 3F) , diffuse microglial activation as well as formation of microglial nodules (Fig. 3B) .
Upregulation of the A1R Within the Lesions of RE
The immunostaining of A1R was studied by immunohistochemistry in brain specimens of RE patients and surgical control. In control gray matter, A1R immunoreactivity was present exclusively in perinuclear (cytoplasm) of neuronal cells (Fig. 4A, B) . In RE specimens, strong A1R immunoreactivity was remarkable observed in the neuronal cells with a predominant perinuclear (cytoplasmic) localization in gray matter (Fig. 4C-H) . In addition, some A1R staining was demonstrated in endothelial cells (Fig. 4E, F , inset arrowheads) and dysmorphic neurons (Fig. 4C, D, inset arrowheads) . Immunohistochemistry analysis revealed a significant increase in the density of A1R immunoreactivity within the mild (n ¼ 12), the moderate (n ¼ 12) as well as the most severe (n ¼ 12) inflamed/neuron-depleted area (p < 0.01, respectively) compared with controls (n ¼ 6) (Fig. 4I) . Double labeling of A1R with NeuN confirmed perinuclear localization of A1R in neuronal cells within the lesion area, with the 81.8%, 75.1%, and 67.9% of residual neurons that were A1R immunoreactive in mild, moderate, and severe RE ( Fig. 5A-C ; Table 2 ). Double labeling of A1R with GFAP or Iba-1 demonstrated that neither A1R-positive reactive astrocytes (Fig. 5D-F) nor A1R-positive activated microglial cells (Fig. 5G-I ) was detected within the lesions.
Western blot analysis was performed to quantify the total amount of A1R in total homogenates of surgical cortex from RE patients and surgical control cortex. Western blot results revealed a significant increase of A1R expression (p < 0.05) in RE (n ¼ 5) compared to control specimens (n ¼ 5).
Upregulation of the ADK Within the Lesions of RE
Similar with previous studies (11, 28, 30) , ADK immunoreactivity was present in sparse astroglial cells with only a weak staining (Fig. 6A, B , inset arrowheads) and lack of ADK immunoreactivity in neuronal cells (Fig. 6A, B , inset arrows) in surgical control cortex. In RE specimens, ADK immunoreactivity was remarkably observed in the reactive astroglial cells in the lesion area, with a predominant cytoplasmic localization ( Fig. 6C-H, arrowheads) . In addition, ADK was also observed in a subpopulation of the remaining neuronal cells in the lesion area, with a predominant cytoplasmic localization (Fig. 6D, F, arrows) . Immunohistochemistry analysis revealed a significant increase in the density of ADK immunoreactivity within the mild (n ¼ 12), the moderate (n ¼ 12) as well as the most severe (n ¼ 12) inflamed/neuron-depleted area (p < 0.05, p < 0.05, and p < 0.01, respectively) compared with controls (n ¼ 6) (Fig. 6I) . Double labeling of ADK with GFAP or NeuN confirmed that ADK expressed in GFAP-positive react- ive astrocytes (Fig. 7D-F, arrows) , and a subpopulation of the remaining neuronal cells with 38.5%, 47.1%, and 56.7%, respectively, within lesions area in the mild, moderate, and severe RE (Fig. 7A -C, arrows; Table 2 ).
Western blot analysis was performed to quantify the total amount of ADK in total homogenates of control surgical cortex (n ¼ 5) and surgical cortex from RE patients (n ¼ 5) (Fig. 8A) . There was significantly greater ADK expression (p < 0.05) in RE vs control specimens (Fig. 8B) .
DISCUSSION
A large number of studies have validated the concept that adenosine, acts as an endogenous neuromodulator with anticonvulsion (17, 18, 21, 37) , antiinflammation (16) , and restoring cognitive function when cognition is impaired secondary to epilepsy (13, 38) . Disruption of adenosine homeostasis has been linked with epilepsy, inflammation and cognitive dysfunction. It has been proved that the alteration of adenosine receptors and the major adenosine-removing enzyme ADK contribute to the disruption of adenosine homeostasis in epilepsy (13) .
Neuronal excitability in the brain is modulated by activation of G protein coupled adenosine receptors (A1, A2A, A2B, and A3) (15, 39) . The receptors expression levels and availability of endogenous adenosine to activate the receptors plays a crucial role in neuronal excitability (13) . Adenosine is a neuromodulator that has been proved to be major endogenous anticonvulsant acting via A1R. A1R are enriched in the central nervous system, where they are expressed in the cerebral cortex, hippocampus, cerebellum, thalamus, and brainstem (40) . In the brain, adenosine modulates neuronal activity by decreasing presynaptic release of various neurotransmitters, and the most dramatic inhibitory actions are on the glutamatergic system (40) . In addition, adenosine acting through postsynaptic A1Rs may activate Kþ channels, leading to hyperpolarization of postsynaptic neurons and promoting NMDA receptor inhibition (41) .
Previous data from different experimental models and clinical evidence suggest that dysregulation of A1R signaling is intimately linked to the pathophysiology of epilepsy (23, 32, (42) (43) (44) . In the present study, we assessed the neuronal expression of the A1R in the focal lesion of the RE brain. To our knowledge, this is the first study to describe the alteration of A1R in RE brain. In the present study, we demonstrate intralesional increased A1R protein levels in the specimens from RE patients with medically intractable epilepsy. Immunohistochemical data have shown A1R immunoreactivity in predominant perinuclear (cytoplasm) of neuronal cells, which is markedly increased in RE patients. No other cells, including reactive astrocytes and activated microglia, have been recognized with A1R immunoreactivities. Western blot analysis also demonstrated upregulation of A1R expression in RE patients compared with surgical controls. The increase in the protein levels of A1R in RE was similar with human Creutzfeldt-Jakob disease and rodent encephalitis (45, 46) . The possible reason for upregulation of A1R in the brain is that neuroinflammation itself may also affect the expression of A1R, especially the nature of ongoing process of inflammation in RE leads to the increase of the expression of A1R. Characteristic clinical features of RE suggest a relatively restricted disease phenotype. First, unilateral epileptic discharge with or without unihemispheric slowing in longterm video EEG, and EPC is not always accompanied by visually recognizable ictal surface EEG activity. Second, seizures, inflammation and atrophy are generally restricted to 1 cerebral hemisphere; only 2 published cases of Rasmussen's encephalitis reported evidence of bilateral disease on histopathology.
Importantly, no case of contralateral involvement has been reported after surgical treatment of unilateral RE (even when judged by clinical criteria) (4). Third, most seizures are focal (simple or complex partial seizures) with or without EPC; and notably, secondary generalized epilepsia continua from EPC has rarely been reported. It is well known that A1R activation is needed to prevent seizures spread and seizures-induced damage (18, 23, 26, 44, 47) . The present study supports the neuroprotective role of adenosine via A1R in limiting the pathologic changes and seizures of RE. This is evidenced by the relative density of immunoreactivity of A1R that was statistically significantly increased compared with controls, in residual neurons with positivity affecting 81.8%, 75.1%, and 67.9%, respectively, in the mild, moderate, and severe RE, as well as in lesional vascular endothelial cells. This is despite high levels of ADK expression by the surrounding glial cells, and notably in a subset of lesional neurons representing 38.5%, 47.1%, and 56.7% of residual neurons in the mild, moderate, and severe RE, that may be part of the pathophysiology of RE or represent a revertant fetal expression pattern (Table 2) .
Adenosine kinase has been extensively studied in experimental epilepsy models (18, 25, 48) and in patients with intractable epilepsy such as temporal epilepsy (19, 28) , tumorrelated epilepsy (29), Rasmussen encephalitis (11), and focal cortical dysplasia (30) . Dysregulation of ADK plays a significant role in the processes that turn a normal brain into an epileptic brain (13) . Adenosine kinase is, therefore, a potential target for antiepileptogenesis or disease modification by activation of multiple adenosine receptors-dependent pathways (18, 24, 25) .
Developmental studies performed in mice indicate that there is a switch from neuronal expression during the perinatal period to near exclusive astrocytic expression in the adult brain (49) . Interestingly, strong neuronal expression of ADK has been detected in human fetal brains (gestational week 13; temporal cortex); high levels observed by Western blot analysis in total cortical homogenates may reflect the expression in the deep compartments of the cortical wall (ie ventricular/ subventricular zone) at early stages of corticogenesis (50) . Analysis on human specimens from autopsy control and surgical control demonstrated ADK immunoreactivity was present in sparse glial cells with only a weak staining, and lack of expression in most of the neurons in the cortex (11, 19, 28, 30) . Our recent study demonstrated no difference in ADK expression between children (more than 3 years) and adult autopsy control cortex. Further study is needed on younger children (eg 1 month, 6 months, 1 year, 2 years, and 3 years) for the developmental and age-related differences (30) . Our recent study has demonstrated that upregulation of astrocytic ADK expression in RE patients with intractable epilepsy (11, 30) . In the present results, in addition to the overexpression of astrocytic expression of ADK in the lesion area, increased cytoplasmic expression of ADK was also observed in a subpopulation of the remaining neuronal cells in the lesion area, with a predominant cytoplasmic localization. Experimental and clinical evidence demonstrated that overexpression in astrocytic ADK associated with reactive astrogliosis and consequential development of adenosine deficiency is a hallmark in epileptogenesis (18, 19) . However, little is known about the functional implication of neuronal ADK in human brain. Although most of the neuronal cells are the terminally differentiated cells and lack the ADK expression, these cells can constitute a major source for the direct release of adenosine (51) . It has been proved that ADK-tg mice constitutive overexpression of transgenic ADK throughout the brain, with particularly high levels in hippocampal pyramidal neurons were shown to be sufficient to down-regulate of the tissue concentration of adenosine (52) , sufficient to generate electrographic seizures, contributing mechanism for seizures generation in epilepsy (18, 19) . The neuronal expression of ADK in the lesion of RE cortex maybe inflammation associated (11) . A recent study has demonstrated that inflammation associated molecules such as interleukin-1b and lipopolysaccharide could play a role in the upregulation of ADK levels in astrocytes, providing a potential additional layer of modulatory cross talk between the astrocyte-based adenosine cycle and inflammation (28) . In addition to the overexpression of astrocytic ADK in RE cortex, neuronal expression of ADK may decrease extracellular adenosine levels and subsequently increased seizures activity. Another hypothesis on neuronal expression of ADK in RE is that the early stage of developmental microenvironment alteration may impair the temporal transient expression pattern of neuronal ADK from fetal to postnatal brains (49, 50) .
As the major adenosine removing kinase, ADK plays an important role in modulation of cognitive process. Transgenic overexpression of ADK in the brain of mice (Adk-tg mice) caused prominent cognitive impairment on several levels (53, 54) . In line with this finding, Adk-tg mice displayed severe learning deficits in the domains of reference memory, working memory, and associative learning (53) . It is also well documented that extracellular adenosine has potent antiinflammatory properties (55) , that is, increases of extracellular adenosine levels turn off local inflammatory responses to decrease cellular damage in the surrounding tissue (55) . Increased expression of ADK in the involved cerebral hemisphere in RE patients, which may explain the natural history of RE, that is, deterioration of cortical inflammation, lower seizures threshold, and development of pharmacoresistant focal epilepsy and EPC over time.
In conclusion, over-expression of the major adenosine removing enzyme ADK in reactive astrocytes and subpopulation of remaining neurons in RE patients plays an important role in the epileptogensis of RE. On the other hand, increased neuronal A1R expression in RE may be involved in prevention of seizures spread and seizures-induced damage, limitation of both seizures and inflammation atrophy in 1 cerebral hemisphere. Our findings suggest adenosine A1R signaling plays a crucial role in the pathophysiology (likely restricting the clinical phenotype) of RE due to its anticonvulsive, antiinflammatory, and cognitive neuroprotective abilities. Therefore, adenosine augmenting therapeutic strategies should be actively explored in the treatment for RE.
We acknowledge limitations to the current study. Because we analyzed a relatively small cohort of patients, we cannot exclude the influence of clinical variables. Moreover, adenosine A2A receptors (A2A) antibody did not work in the present experiment. Adenosine is reported to act as a neuromodulator in the central nervous system by a balanced activation of inhibitory A1R and facilitatory A2AR. A2AR has been shown to have a widespread distribution in brain, play a crucial role in synaptic plasticity, counteract the A1R-mediated inhibition of synaptic transmission, increase in expression in neurons and glial cells upon injury, and act as a STOP signal of the immune-inflammatory system (56) . Therefore, the expression patterns and regulation of adenosine receptors A2A in RE deserve further investigation.
